DLOC Biosystems to build organ-on-a-chip facility in Discovery Park

DLOC Biosystems has selected Discovery Park, Kent, as the location for its new biology facility. The company will set up a biology lab within Discovery Park’s thriving life science cluster to continue development of its state-of-the-art organ-on-a-chip technology and deliver accurate assay testing services to pharmaceutical companies to advance drug discovery.

DLOC Biosystems was founded to enable faster, safer and cheaper drug development. The company’s chips provide an environment where cells can grow and reorganise into tissues, providing the perfect setting for large scale, affordable drug testing. Its technology will help to enable the reduction and replacement of animal testing, by providing more accurate data on safety and efficacy than current pre-clinical testing models.

With an engineering team based in Lebanon, DLOC was looking to build a new biology team based in the UK. The company selected Discovery Park’s high-spec lab facilities just over an hour from London due to its reputation as a leading hub for life sciences and the opportunity it offers for future expansion. Discovery Park’s extensive ecosystem provides future opportunities for collaboration as well as a network of potential customers, a key consideration for life science start-ups.

Wadah Malaeb, CEO and Founder of DLOC Biosystems, commented: “We were initially interested in locating in London as it offered access to an excellent talent pool, however, the cost and availability of high-spec lab space as well as living costs for potential employees proved inhibitive. When I visited Discovery Park, I was impressed not just by the quality of the facilities available, but also by the extensive business support offered by the team. The park and its surroundings provide an ideal location to build our business and I look forward to joining the Discovery Park community.”

Chris Broom, Head of Business Development at Discovery Park, added: “We’re passionate about supporting the transformation of ideas into successful commercial innovation. As well as access to our cutting-edge facilities, DLOC will have the opportunity to network and collaborate with our community of innovative start-ups and established companies. We are excited to welcome Wadah and his team to Discovery Park and look forward to working with them to support the growth of the company and deliver significant benefits to the drug discovery industry.”

DLOC is currently recruiting a biology team leader to start and build its new team at Discovery Park and will also expand its engineering team on site. It is also participating in the Discovery Spark programme for life science start-ups to develop and refine its business offering.

 

More news and updates 

DLRC achieves King’s Award for Enterprise in International Trade

DLRC Ltd has been honoured with the King’s Award for Enterprise, recognising its outstanding performance in international trade. This places DLRC among a select group of only 252 organisations in the UK to receive this prestigious award.

Optibrium partners with FMC Corporation to transform agrochemical discovery

Optibrium’s AI-powered discovery platform Cerella™ chosen by FMC to accelerate its agrochemical discovery pipeline.

Touchlight Genetics and NPL awarded grant to develop novel gene-length single-stranded genome editing template

Touchlight Genetics, in partnership with the National Physical Laboratory (NPL) have secured funding from Innovate UK under their Innovative Technologies: Nucleic Acid Medicines Manufacture, Round 2 call. 

PrecisionLife and Metrodora Institute launch clinical trials to accelerate treatment of ME/CFS and long Covid patients

Up to 1,000 patients being recruited into targeted precision medicine clinical trials expected to readout results as early as this year; trials are designed to provide validation of safety and effectiveness for novel diagnostics and innovative clinical care pathways in ME/CFS and Long Covid.

European Life Sciences sector primed for growth in 2024 driving real estate demand and investment opportunities

The European Life Science sector has been marked by strong growth and resilience in recent years and is set for significant expansion in 2024, driven by new medical treatments and both private and public funding according to JLL’s Life Sciences Industry & Real Estate Perspective report.

Ingenza expanding codABLE® gene design algorithm to aid recombinant protein production in yeast

Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE® machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to fine-tune codon usage, ensuring seamless compatibility with the production host and maximising production yields.

Arecor and Medtronic Diabetes establish collaboration to develop novel thermostable insulin for implantable pump delivery

Medtronic to fund Arecor’s development of Arestat™ enabled novel, high concentration, thermostable insulin, specifically tailored for use in combination with a next-generation implantable pump

Infinitopes secures £12.8 million seed financing to enhance its Precision ImmunomicsTM antigen discovery technologies

Infinitopes Precision Immunomics, an integrated cancer biotech combining world-leading platforms in precision antigen discovery with vaccine vectors capable of durably stimulating protective immune responses, today announced the completion of a £12.8 million seed funding round led by Octopus Ventures.

Business Opportunity: Advance your workforce with a Bioscience Degree Apprenticeship

Manchester Metropolitan University have opened applications for the Laboratory Science Degree Apprenticeships in Bioscience. New cohorts are set to begin in September.

Poolbeg Pharma plc announces exclusive option agreement to acquire Orphan Drug Candidate for Behçet's Disease

Poolbeg Pharma plc announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc, for a nominal fee, to acquire a novel topical muco-adherent formulation of Pentoxifylline (tPTX) for the treatment of oral ulcers in patient's suffering from Behçet's Disease.

 

More within